The global mild cognitive impairment (MCI) treatment market is characterized by a growing prevalence of MCI, a condition characterized by a slight but noticeable decline in cognitive abilities, including memory and thinking skills. MCI is considered a transitional stage between normal aging and dementia, such as Alzheimer's disease. The global population is aging, leading to a higher prevalence of age-related cognitive disorders such as MCI. This demographic trend is a key driver of the MCI treatment market. The market is competitive, with key players focusing on developing novel treatments and therapies. These include pharmaceutical companies developing drug therapies, as well as companies offering non-pharmacological interventions such as cognitive training and rehabilitation programs. The market is expected to continue growing as the prevalence of MCI increases and as advancements in treatment options continue to evolve.
Data Bridge Market Research analyses that the Global Mild Cognitive Impairment (MCI) Treatment Market is growing with a CAGR of 8.7% in the forecast period of 2022 to 2029 and is expected to reach USD 148,373.70 thousand by 2029.
To know more, visit https://www.databridgemarketresearch.com/reports/global-mild-cognitive-impairment-mci-treatment-market
Below are the Top Five Mild Cognitive Impairment (MCI) Treatment Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Eisai Co., Ltd.
|
Eisai Co., Ltd. is particularly known for its focus on Alzheimer's disease and related conditions. Eisai has a strong presence in the market due to its innovative research and development efforts, as well as its commitment to improving the lives of patients with cognitive disorders. Eisai has several products and therapies in development for the treatment of MCI and related conditions. One of its key products is donepezil, which is marketed under the brand name Aricept and is used to treat MCI and mild to moderate Alzheimer's disease.
|
|
Americas, Middle East and Africa, Europe, and Asia-Pacific
|
In January 2022, Eisai announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, and of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use early Alzheimer’s disease, including details of the study’s goal for diverse enrolment and primary endpoint. This will help the company to increase diversity in clinical trials.
|
|
2.
|
Teva Pharmaceuticals Industries Ltd.,
|
Teva Pharmaceuticals USA, Inc. is a significant player in the Global Mild Cognitive Impairment (MCI) Treatment Market, known for its focus on developing generic and branded pharmaceutical products for various therapeutic areas, including neurology and psychiatry. Teva offers a range of products for the treatment of MCI and related conditions, including generic versions of medications commonly used to manage cognitive impairment. These medications may include cholinesterase inhibitors, which are commonly used to improve cognitive function in patients with MCI and Alzheimer's disease.
|
|
North America, Europe, South America, and Asia-Pacific
|
In April 2021, Teva and Launch Therapeutics signed a Clinical Collaboration Agreement to expedite the development of a Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program. In addition, Teva and Abingworth entered into a Strategic Development Funding Agreement.
|
|
3.
|
Novartis AG
|
Novartis offers a range of products for the treatment of MCI and related conditions, including medications that target cognitive function and disease progression. One of its key products is rivastigmine, which is marketed under the brand name Exelon and is used to treat mild to moderate Alzheimer's disease and MCI. Rivastigmine is a cholinesterase inhibitor that helps improve cognitive function by increasing the levels of neurotransmitters in the brain.
|
|
Americas, Middle East and Africa, Europe, and Asia-Pacific
|
In May 2024, Novartis announced an agreement to acquire Mariana Oncology, a biotechnology company in Watertown, Massachusetts. Mariana Oncology is focused on developing novel radioligand therapies (RLTs) for cancers with high unmet patient need. This acquisition strengthens Novartis' RLT pipeline and enhances its research infrastructure and clinical supply capabilities. The acquisition aligns with Novartis' strategic priorities in oncology and RLT platform innovation.
|
|
4.
|
Viatris Inc.
|
Viatris offers a range of generic medications for the treatment of cognitive impairment, including cholinesterase inhibitors and other medications commonly used to manage MCI and Alzheimer's disease. These generic medications provide cost-effective treatment options for patients with cognitive disorders. In addition to generic medications, Viatris is also involved in the development of innovative therapies for MCI.
|
|
North America, Europe, and Asia-Pacific
|
In March 2024, Viatris Inc. received notification that Mapi Pharma Ltd. had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for GA Depot 40 mg. Both companies are currently reviewing the contents of the CRL and will be deciding on the appropriate next steps. Despite this setback, both companies remain confident in the potential of GA Depot 40 mg to offer a significant new treatment option for patients with multiple sclerosis.
|
|
5.
|
Sun Pharmaceutical Industries Ltd.
|
Sun Pharmaceutical Industries Ltd. is a significant player in the Global Mild Cognitive Impairment (MCI) Treatment Market, known for its focus on developing and manufacturing generic and specialty pharmaceuticals. Sun Pharma offers a range of generic medications for the treatment of cognitive impairment, including cholinesterase inhibitors and other medications commonly used to manage MCI and Alzheimer's disease. These generic medications provide cost-effective treatment options for patients with cognitive disorders.
|
|
North America, Africa, Europe, South America, and Asia
|
In October 2023, Sun Pharma and Zydus signed a licensing agreement to co-market Desidustat, an important treatment for patients with Chronic Kidney Disease, in India.
|
Conclusion
The global mild cognitive impairment (MCI) treatment market is characterized by the presence of several key players, including Eisai Co., Ltd., Teva Pharmaceuticals USA, Inc., Novartis AG, Viatris Inc., and Sun Pharmaceutical Industries Ltd. These companies offer a range of generic and branded pharmaceutical products for the treatment of MCI and related conditions, contributing to the advancement of treatment options for patients with cognitive impairment. The market is driven by factors such as the increasing prevalence of MCI, growing awareness and early diagnosis, advancements in diagnostic technologies, increasing research and development efforts, and government initiatives and support. These factors are expected to continue driving market growth.
